Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 percent of their total body weight over the 72-week trial. SUBSCRIBE LOG IN ...

Endocrinology > Obesity Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says — Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

Eli Lilly's tirzepatide helped people lose up to 50 pounds, the sort of weight loss results only consistently seen with bariatric surgery. ... The trial was run in the U.S., Argentina, Brazil, ...

Diabetes drug promotes weight loss. Tirzepatide is part of a new class of drugs called called GLP-1 ... controlled clinical trial demonstrated that tirzepatide led to a 20 percent reduction ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.